Clinical Trial: Furmonertinib Dose-Escalation Plus Bevacizumab with VP Shunt and Intrathecal Pemetrexed in EGFR-Mutant NSCLC with Leptomeningeal Metastases: A Phase II Study (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Furmonertinib Dose-Escalation Plus Bevacizumab with VP Shunt and Intrathecal Pemetrexed in EGFR-Mutant NSCLC with Leptomeningeal Metastases: A Phase II Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131551

Registration Time: 2026/09/03

Type: Interventional study

Primary Sponsor: Shanghai Pulmonary Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335932

Published by HT Digital Content Services with permission from Health Daily Digest....